PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Acurx Pharmaceuticals, Inc. (ACXP)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00510M1045
CUSIP00510M104
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$38.60M
EPS-$1.15
Year Range$1.17 - $8.82
Target Price$12.09
Short %2.21%
Short Ratio3.99

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Acurx Pharmaceuticals, Inc.

Popular comparisons: ACXP vs. LLY

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Acurx Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-60.00%-40.00%-20.00%0.00%20.00%NovemberDecember2024FebruaryMarchApril
-67.45%
15.51%
ACXP (Acurx Pharmaceuticals, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Acurx Pharmaceuticals, Inc. had a return of -56.66% year-to-date (YTD) and -45.39% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-56.66%5.90%
1 month-38.97%-1.28%
6 months-67.45%15.51%
1 year-45.39%21.68%
5 years (annualized)N/A11.74%
10 years (annualized)N/A10.50%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-14.62%-12.23%-14.63%
2023-22.28%256.67%-34.21%8.81%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ACXP is 31, suggesting that the investment has average results relative to the market in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.

The Risk-Adjusted Performance Rank of ACXP is 3131
Acurx Pharmaceuticals, Inc.(ACXP)
The Sharpe Ratio Rank of ACXP is 3232Sharpe Ratio Rank
The Sortino Ratio Rank of ACXP is 4040Sortino Ratio Rank
The Omega Ratio Rank of ACXP is 3939Omega Ratio Rank
The Calmar Ratio Rank of ACXP is 2020Calmar Ratio Rank
The Martin Ratio Rank of ACXP is 2323Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Acurx Pharmaceuticals, Inc. (ACXP) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ACXP
Sharpe ratio
The chart of Sharpe ratio for ACXP, currently valued at -0.37, compared to the broader market-2.00-1.000.001.002.003.00-0.37
Sortino ratio
The chart of Sortino ratio for ACXP, currently valued at 0.04, compared to the broader market-4.00-2.000.002.004.006.000.04
Omega ratio
The chart of Omega ratio for ACXP, currently valued at 1.01, compared to the broader market0.501.001.501.01
Calmar ratio
The chart of Calmar ratio for ACXP, currently valued at -0.52, compared to the broader market0.001.002.003.004.005.00-0.52
Martin ratio
The chart of Martin ratio for ACXP, currently valued at -1.12, compared to the broader market-10.000.0010.0020.0030.00-1.12
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.89, compared to the broader market-2.00-1.000.001.002.003.001.89
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.74, compared to the broader market-4.00-2.000.002.004.006.002.74
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.43, compared to the broader market0.001.002.003.004.005.001.43
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.62, compared to the broader market-10.000.0010.0020.0030.007.62

Sharpe Ratio

The current Acurx Pharmaceuticals, Inc. Sharpe ratio is -0.37. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.002.503.00NovemberDecember2024FebruaryMarchApril
-0.37
1.89
ACXP (Acurx Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Acurx Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-78.96%
-3.86%
ACXP (Acurx Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Acurx Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Acurx Pharmaceuticals, Inc. was 83.78%, occurring on Oct 3, 2023. The portfolio has not yet recovered.

The current Acurx Pharmaceuticals, Inc. drawdown is 78.96%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-83.78%Jun 28, 2021571Oct 3, 2023

Volatility

Volatility Chart

The current Acurx Pharmaceuticals, Inc. volatility is 29.70%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%NovemberDecember2024FebruaryMarchApril
29.70%
3.39%
ACXP (Acurx Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Acurx Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items